Citigroup
MOLN

Citigroup’s Molecular Partners MOLN Stock Holding History

Citigroup’s Portfolio MOLN Stock Details MOLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,000
Closed -$40K – 5884
2022
Q3 		$40K Hold
6,000
– – ﹤0.01% 4482
2022
Q2 		$40K Buy
+6,000
New +$61.8K ﹤0.01% 4635

Other funds holding MOLN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citigroup's MOLN Position: Q4 2022 in Review

Citigroup sold out of Molecular Partners (MOLN) in Q4 2022, closing a stake of 6,000 shares — an estimated $40K sold.

Citigroup first reported a position in MOLN in Q2 2022 and held it in 2 quarters. The position peaked at $40K in Q3 2022. 8 funds tracked by Wall St. Rank hold MOLN as of Q4 2022.

  • Citigroup reported no remaining Molecular Partners position as of Q4 2022 after selling out during the quarter.
  • Citigroup sold 6,000 Molecular Partners shares in Q4 2022, an estimated $40K.
  • Citigroup first reported a position in Molecular Partners in Q2 2022 and held it in 2 quarters.
  • Citigroup's Molecular Partners position peaked at $40K in Q3 2022.
  • 8 funds tracked by Wall St. Rank held Molecular Partners as of Q4 2022.

Based on Citigroup's 13F filing for Q4 2022, filed 9 Feb 2023.